Everest Organics is currently trading at Rs. 151.90, up by 1.40 points or 0.93% from its previous closing of Rs. 150.50 on the BSE.
The scrip opened at Rs. 164.95 and has touched a high and low of Rs. 164.95 and Rs. 147.20 respectively.
The BSE group 'X' stock of face value Rs. 10 has touched a 52 week high of Rs. 189.50 on 31-Jan-2019 and a 52 week low of Rs. 57.15 on 29-Oct-2018.
Last one week high and low of the scrip stood at Rs. 164.95 and Rs. 146.60 respectively. The current market cap of the company is Rs. 120.00 crore.
The promoters holding in the company stood at 73.27%, while Institutions and Non-Institutions held 0.03% and 26.71% respectively.
Everest Organics has opened its new Research and Development (R&D) Center at its factory Aroor, in Hyderabad. The company’s new R&D center is a sign of the company's continued commitment to the API's industry and bringing new job opportunities to the local community.
The Research and Development Center is state of art analytical, quality control and fully-equipped lab with well trained experts in a single facility. The center will accelerate growth of the company's portfolio of innbvative technologies and products that overcome shortage in intermediates, process challenges and will provide hands-on support to assist customers in their drug development.
Everest Organics is a fast growing API and Bulk drug manufacturing company with world class facility and it’s committed to manufacturing excellent quality products and customer service.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1951.50 |
| Dr. Reddys Labs. | 1226.10 |
| Cipla | 1429.60 |
| Lupin | 2498.05 |
| Zydus Lifesciences | 1154.70 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: